Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Science Board to convene in August

This article was originally published in The Tan Sheet

Executive Summary

FDA's scientific advisory panel will meet Aug. 17 in Rockville, Md., to discuss plans for an "additional subcommittee for the review of research" at the Center for Food Safety and Applied Nutrition, as well as receive updates on the agency's assessment of bisphenol A (1"The Tan Sheet" March 2, 2009, In Brief)

You may also be interested in...



FDA updates on BPA activities

Infant formula manufacturers are testing product samples on an ongoing basis to minimize bisphenol A in food contact applications and identify safe levels of the chemical. The Center for Food Safety and Applied Nutrition is analyzing several infant formula brands with an updated testing method, Mitchell Cheeseman, deputy director of the Office of Food Additive Safety, said at an FDA Science Board meeting Feb. 24 in Gaithersburg, Md. Recent testing of 57 samples found a range of 0.02 to 10.55 µg of BPA per kg of infant formula, which Cheeseman calls "comparable to the existing data" on formula products. He added that FDA encourages industry to follow a voluntary "code of practice" - essentially good manufacturing practices for producing and filling infant formula cans - "to minimize BPA migration from existing packaging materials into" the product. The presentation was part of an ongoing dialog about BPA's safety in food contact applications (1"The Tan Sheet" Feb. 16, 2009, In Brief)

Bankruptcy Court Gives Green Light To Akorn Sale

Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.

Dr Reddy’s Enters OTC Eyecare Space

Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel